MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)

NCT00420420 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

144

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: MK0249
DRUG: Comparator: Placebo (unspecified)

Sponsor

Merck Sharp & Dohme LLC